Skip to main content

Syndax Pharmaceuticals Inc 8-K, filed Nov 2, 2026

Syndax Pharmaceuticals Inc (SNDX)

8-K 2026-11-02 For: 2026-11-02
View Original
Added on November 02, 2026

About this 8-K

Syndax Pharmaceuticals Inc filed this 8-K on November 2, 2026.

Syndax Pharmaceuticals appointed Aaron A. Ondrey CFO effective November 9, 2026, succeeding retiring Keith A. Goldan. Ondrey receives a $543,000 annual salary, 45% target bonus and option for 270,000 shares. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 5.02: Director or officer change, or executive pay
  • Item 9.01: Financial statements and exhibits